Keros Therapeutics KROS
NASDAQ KROS
$11.20 -0.20 (-1.75%)
As of: Oct 21, 2026 · 1:02 PM EDT

Keros Therapeutics (KROS) Receivables - Other (2019 - 2020)

Updated

Keros Therapeutics' Receivables - Other was $805,000 in Q1 2020, down 10.6% from the prior quarter.

Analysis

Keros Therapeutics (KROS) Receivables - Other (2019 - 2020) Analysis & Trends

At the end of FY2019, Receivables - Other at Keros Therapeutics came in at $922,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,133.08 Bn 1,101.67 Bn 19.71 Bn
2 Johnson & Johnson 616.40 Bn 534.93 Bn 17.26 Bn
3 AbbVie 501.19 Bn 474.31 Bn 12.70 Bn
4 Merck 367.18 Bn 321.56 Bn 12.21 Bn
5 Novartis Ag 297.99 Bn 261.98 Bn 11.24 Bn
6 Astrazeneca 261.67 Bn 235.36 Bn 12.86 Bn
7 Amgen 235.57 Bn 190.97 Bn 7.24 Bn
8 Gilead Sciences 190.62 Bn 164.82 Bn 6.22 Bn
9 Pfizer 169.63 Bn 116.28 Bn 10.94 Bn
10 Keros Therapeutics 221.76 Mn -1.71 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2020 805,000.00
Dec 31, 2019 900,000.00
API Access

Keros Therapeutics Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=KROS&period=max&api_key=YOUR_API_KEY